Sagimet Biosciences Inc.

Contributing Author

Recent Articles by Sagimet Biosciences Inc.

2 hours	Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock SGMT +33.79% GlobeNewswire
2 hours	Sagimet Biosciences Provides Strategic and Corporate Updates SGMT +33.79% GlobeNewswire
Apr-20	Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer SGMT GlobeNewswire
Apr-06	Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SGMT GlobeNewswire
Mar-11	Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates SGMT GlobeNewswire
Feb-25	Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences SGMT GlobeNewswire
Feb-05	Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences SGMT -10.53% GlobeNewswire
Feb-02	Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne SGMT +9.88% GlobeNewswire
Jan-08	Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference SGMT GlobeNewswire
Dec-18	Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination SGMT GlobeNewswire
Dec-17	Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet's Fixed Dose Combination Program SGMT GlobeNewswire
Dec-10	Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration SGMT GlobeNewswire
Dec-09	Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SGMT GlobeNewswire
Nov-20	Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference SGMT -7.39% GlobeNewswire
Nov-13	Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates SGMT -12.24% GlobeNewswire
Nov-10	Sagimet Biosciences Presents Two Denifanstat Posters at AASLD-The Liver Meeting 2025 SGMT +10.77% GlobeNewswire
Oct-24	Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference SGMT +24.69% GlobeNewswire
Oct-14	Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences SGMT GlobeNewswire
Oct-07	Sagimet Biosciences Announces Upcoming Presentation at AASLD-The Liver Meeting 2025 SGMT GlobeNewswire
Oct-01	Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination SGMT GlobeNewswire
Sep-24	Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week SGMT +8.17% GlobeNewswire
Sep-17	Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis SGMT GlobeNewswire
Sep-10	Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit SGMT GlobeNewswire
Aug-26	Sagimet Biosciences to Participate in Two Upcoming Investor Conferences SGMT GlobeNewswire
Aug-13	Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates SGMT GlobeNewswire
Aug-05	Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference SGMT +6.04% GlobeNewswire
Jun-09	Sagimet Biosciences to Host Virtual KOL Event, "A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne" on June 16, 2025 SGMT GlobeNewswire
Jun-04	Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis SGMT +12.40% GlobeNewswire
May-22	Sagimet Biosciences to Host Virtual KOL Event, "Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)" on May 29, 2025 SGMT +5.90% GlobeNewswire
May-08	Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates SGMT GlobeNewswire

Sagimet Biosciences Inc.

Recent Articles by Sagimet Biosciences Inc.

Upgrade your Finviz experience